Peritoneal Carcinomatosis (PC) is considered as a terminal disease with short survival. It is treated with palliative therapies, consisting of repeated drainages and sometimes instillation of chemotherapy. Since the nineties, surgery has been combined with more effective systemic chemotherapy, intraperitoneal chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of PC. This combination therapy significantly increases the overall survival of selected PC patients. The understanding of how intraperitoneal chemotherapy and HIPEC can cure patients is still unclear. Experts hypothesized that the efficacy is obtained by the ability of high peritoneal drug exposure and hyperthermia to directly kill cancer cells. Several studies indicate that cancer cells death directly influences the response of the immune system. For this reason, the protective effect of intraperitoneal chemotherapy and HIPEC could be mediated by its ability to kill cancer cells in an immuno-genic way, causing an efficient anticancer immune response. In this review, we investigate the role of the innate peritoneal or locoregional therapy-induced immune response in PC therapy.

中文翻译：

---

腹膜癌病的免疫反应和局部治疗。

腹膜癌（PC）被认为是一种生存期短的绝症。它采用姑息疗法进行治疗，包括反复引流和有时滴注化疗。自九十年代以来，手术与更有效的全身化疗、腹腔内化疗和腹腔内热疗（HIPEC）联合治疗PC。这种联合疗法显着提高了选定 PC 患者的总体存活率。对腹腔内化疗和 HIPEC 如何治愈患者的理解仍不清楚。专家推测，这种疗效是通过高腹腔药物暴露和热疗直接杀死癌细胞的能力获得的。多项研究表明，癌细胞死亡直接影响免疫系统的反应。因此，腹腔化疗和 HIPEC 的保护作用可能是通过其以免疫原性方式杀死癌细胞的能力来介导的，从而引起有效的抗癌免疫反应。在这篇综述中，我们研究了先天性腹膜或局部治疗诱导的免疫反应在 PC 治疗中的作用。